Thus, in the context of viral infections, type 2 DCs exposed to type I IFN cross‐present IC containing viral antigens and prime CD8 T cells.[62] Additional experimental evidence suggests that type 2 DC also contributes to antitumor defense. This evidence concerns the gene CD8A and viral infectious disease.